On August 14, 2026, Haemonetics Corporation entered into a non-exclusive supply agreement with CSL Plasma Inc., allowing CSL to utilize the Company’s NexSys PCS devices with Persona PLUS technology and purchase related disposables in the United States. The agreement does not contain minimum purchase commitments, and while Haemonetics anticipates CSL will transition a portion of its U.S. plasma collection centers to these products, the scope and timing remain undetermined. Consequently, the company is not updating its fiscal 2027 guidance but expects to provide an update on financial impact during its second fiscal quarter earnings call in November 2026. Haemonetics Corporation operates in the medical technology industry, designing and manufacturing devices for blood collection, processing, and storage.

Haemonetics Corporation reported first quarter fiscal 2027 financial results for the period ended June 27, 2026. Total revenue increased 5.6% to $339.4 million, with organic revenue growth of 5.9%. GAAP diluted earnings per share were $0.72, compared to $0.70 in the prior year period, while adjusted diluted EPS rose 3.6% to $1.14. Operating cash flow improved significantly to $52.3 million from $17.4 million a year earlier, resulting in free cash flow of $39.1 million. The company raised its full-year fiscal 2027 guidance, increasing reported revenue growth expectations to 5-8% and organic revenue growth to 4-7%. Haemonetics Corporation operates in the medical technology industry, providing blood management technologies, apheresis systems, and interventional vascular closure solutions.

On July 24, 2026, Haemonetics Corporation elected Martin Madaus to its Board of Directors, effective immediately. Dr. Madaus, currently a Senior Operating Executive at The Carlyle Group, will serve on the Audit Committee and Governance and Compliance Committee, receiving an annual equity award valued at approximately $200,000. Shareholders also approved amendments to the 2019 Long-Term Incentive Compensation Plan, authorizing 4,680,000 additional shares and extending the plan term through 2036, and extended the 2007 Employee Stock Purchase Plan through 2036. The company operates in the medical technology industry, providing apheresis, blood management, and interventional technologies.